Strategic Leadership Exonate has recently appointed Olav Hellebø as Chief Executive Officer, signaling a potential strategic shift and stronger leadership to accelerate partnerships, fundraising, and commercialization efforts in retinal therapeutics.

Early-stage Partnering Historical collaboration with Janssen Pharmaceuticals and ongoing non-invasive eye drop program positions Exonate as an attractive partner for large pharma seeking ophthalmology portfolio expansion and non-invasive delivery platforms.

Clinical milestones Lead asset EXN407 demonstrated favorable endpoints and signals in Phase Ib/IIa for diabetic retinal diseases, suggesting a near-term inflection point that can attract sponsorships, co-development deals, or licensing discussions.

Funding readiness With around $12M in funding and revenue under $1M, Exonate is likely open to strategic investments, grants, or milestone-based partnerships to accelerate clinical development and scale manufacturing for ophthalmology indications.

Global reach readiness Current tech stack and digital presence (hosting, cloud services, and marketing tools) support remote collaboration and international outreach, enabling rapid engagement with potential partners, CROs, and contract manufacturers to advance trials and commercialization.